grant
Continuous glucose monitoring for management of type 2 diabetes in pregnancy (CGM2 trial)
Organization UNIVERSITY OF ALABAMA AT BIRMINGHAMLocation BIRMINGHAM, UNITED STATESPosted 13 Sept 2024Deadline 31 Jul 2029
NIHUS FederalResearch GrantFY20250-11 years old0-4 weeks oldAbdominal DeliveryAddressAdmissionAdmission activityAdult-Onset Diabetes MellitusAffectBilirubinemiaBiologicalBirth InjuriesBirth traumaBlood Glucose Self-MonitoringBlood Sugar Self-MonitoringBrittle Diabetes MellitusC sectionCEACAM7CEACAM7 geneCGM2CesareanCesarean sectionCessation of lifeChildChild YouthChildren (0-21)Chronologic Fetal MaturityComplexConsensusContinuous Glucose MonitorD-GlucoseDataDeathDextroseDiabetes MellitusDiseaseDisorderDisparity populationDystociaEPH GestosisEnsureEthnic OriginEthnicityFastingFetal AgeFoundationsFutureGestationGestational AgeGestational DiabetesGestational Diabetes MellitusGlucoseGoalsGuidelinesHome Blood Glucose MonitoringHyperbilirubinemiaHypoglycemiaIDDMIndividualInfectionInsulin-Dependent Diabetes MellitusIntervention StudiesJuvenile-Onset Diabetes MellitusKetosis-Prone Diabetes MellitusKetosis-Resistant Diabetes MellitusKnowledgeMaturity-Onset Diabetes MellitusMeasuresMethodsMiscarriageMorbidityMorbidity - disease rateNIDDMNeonatal HypoglycemiaNeonatal Intensive Care UnitsNeonatal MortalityNewborn InfantNewborn Intensive Care UnitsNewbornsNon-Insulin Dependent DiabetesNon-Insulin-Dependent Diabetes MellitusNoninsulin Dependent DiabetesNoninsulin Dependent Diabetes MellitusOutcomePatientsPerinatal MortalitiesPerinatal lethalityPerinatal mortality demographicsPopulationPostpartum PeriodPre-EclampsiaPreeclampsiaPregnancyPregnancy ToxemiasPregnancy in DiabetesPregnancy in DiabeticsPregnancy-Induced DiabetesPremature BirthPrematurely deliveringPreterm BirthProteinuria-Edema-Hypertension GestosisProviderRandomization trialRandomizedRandomized, Controlled TrialsRecommendationResearchRiskRisk ReductionShoulderSiteSlow-Onset Diabetes MellitusSpontaneous abortionStable Diabetes MellitusSudden-Onset Diabetes MellitusT1 DMT1 diabetesT1DT1DMT2 DMT2DT2DMTestingTimeType 1 Diabetes MellitusType 1 diabetesType 2 Diabetes MellitusType 2 diabetesType I Diabetes MellitusType II Diabetes MellitusType II diabetesadult onset diabetesadverse consequenceadverse outcomeassess effectivenessbiologiccontinuous blood glucose monitorcontinuous blood sugar monitorcontinuous glucose measurementcontinuous sugar monitordeath among neonatesdeath among newbornsdeath in neonatesdeath in newborndetermine effectivenessdiabetesdiabetes managementdiabetes mellitus managementdiabetic managementdisadvantaged groupdisadvantaged individualdisadvantaged peopledisadvantaged populationdisadvantaged subgroupdisparities across groupsdisparity across subgroupsdisparity among groupsdisparity among subgroupsdisparity between groupsdisparity between subgroupseffectiveness assessmenteffectiveness evaluationeffectiveness testingevaluate effectivenessexamine effectivenessexperiencefastedfastsglucometerglucose meterglucose monitorglycemic controlgroup disparitygroup inequalitygroup inequityhigh risk grouphigh risk individualhigh risk peoplehigh risk populationhypoglycemichypoglycemic episodesimprovedimproved outcomeinequalities among populationsinequalities between populationsinequalities in populationsinequality across populationsinequality among groupsinequality between groupsinequality in groupsinequities among populationsinequities between populationsinequities in populationsinequity across groupsinequity across populationsinequity between groupsinequity in groupsinfantile hypoglycemiainsulin dependent diabetesinsulin dependent type 1intervention researchinterventional researchinterventional studyinterventions researchjuvenile diabetesjuvenile diabetes mellitusketosis prone diabetesketosis resistant diabeteskidslow SESlow socio-economic positionlow socio-economic statuslow socioeconomic positionlow socioeconomic statusmaternal hyperglycemiamaternal morbiditymaternal outcomematurity onset diabetesmeetingmeetingsmortalitymortality among neonatesmortality among newbornsmortality in neonatesmortality in newbornsmother outcomemultidisciplinaryneonatal ICUneonatal deathneonatal demiseneonatal morbidityneonatal outcomeneonatenewborn childnewborn childrennewborn deathnewborn morbiditynewborn mortalityopen labelopen label studyperinatal deathspopulation inequalitypopulation inequitypost-partumpre-eclampticpregnancy diabetespregnancy toxemia/hypertensionpregnantpremature childbirthpremature deliverypreterm deliverypreventpreventingracial minorityrandomisationrandomizationrandomized control trialrandomized trialrandomly assignedreduce riskreduce risksreduce that riskreduce the riskreduce these risksreduces riskreduces the riskreducing riskreducing the riskrisk-reducingsocialsocial disadvantagesocial disparitiessocial factorssocial inequalitystillbirthstillbornstructural determinantsstructural factorssubgroup disparitysuccesstooltype 2 DMtype I diabetestype II DMtype one diabetestype two diabetesunequal groupunequal populationyoungster
Description preview
There is a fundamental knowledge gap in achieving maternal glycemic control sufficient to reduce maternal and neonatal morbidity and mortality in pregnant individuals with type 2 diabetes mellitus (T2DM). Nearly all pregnant individuals with T2DM experience either maternal or newborn morbidity, with worse outcomes seen in socially disadvantaged…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click